Genfit Archives -

Genfit

Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis

Ipsen places €480m bet on Genfit’s liver drug elafibranor

https://pharmaphorum.com/news/ipsen-places-e480m-bet-on-genfits-liver-drug-elafibranor/

Gilead is one of many pharmas chasing mega-bucks promised by the fatty liver disease known as NASH –

Gilead pushes on with NASH partnership with Novo Nordisk

https://pharmaphorum.com/news/gilead-pushes-on-with-nash-partnership-with-novo-nordisk/

France’s Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve

Genfit abandons late-stage trial of NASH drug elafibranor

https://pharmaphorum.com/news/genfit-abandons-late-stage-trial-of-nash-drug-elafibranor/

Genfit has seen almost two-thirds of the value wiped off its shares after its much-anticipated pivotal trial of

Genfit’s NASH hopes are dashed by phase 3 trial fail

https://pharmaphorum.com/news/genfits-nash-hopes-are-dashed-by-phase-3-trial-fail/

Genfit was among a group of NASH companies publishing updates at the International Liver Congress.

Genfit encounters trial recruitment problem in hunt for NASH patients

https://pharmaphorum.com/news/genfit-encounters-trial-recruitment-problem-pharmas-hunt-nash-patients/

Genfit